Page last updated: 2024-10-30

losartan and Cystic Fibrosis

losartan has been researched along with Cystic Fibrosis in 4 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Kim, MD2
Bengtson, CD1
Yoshida, M2
Niloy, AJ1
Dennis, JS2
Baumlin, N2
Salathe, M2
Polineni, D1
Salathe, SF1
David, JK1
Peloquin, CA1
Wanner, A1
Sailland, J1
Whitney, P1
Horrigan, FT1
Sabater, JR1
Abraham, WM1
Bonfield, TL1
Chan, HC1
Law, SH1
Leung, PS1
Fu, LX1
Wong, PY1

Other Studies

4 other studies available for losartan and Cystic Fibrosis

ArticleYear
Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies.
    The Journal of clinical investigation, 2022, 06-01, Volume: 132, Issue:11

    Topics: Benzodioxoles; Cyclooxygenase 2; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulato

2022
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
    American journal of respiratory and critical care medicine, 2020, 02-01, Volume: 201, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Bronchi; Cells, Cultured; Cystic Fibrosis; Disease

2020
Preclinical Modeling for Therapeutic Development in Cystic Fibrosis.
    American journal of respiratory and critical care medicine, 2020, 02-01, Volume: 201, Issue:3

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Inflammation; Losartan

2020
Angiotensin II receptor type I-regulated anion secretion in cystic fibrosis pancreatic duct cells.
    The Journal of membrane biology, 1997, Apr-01, Volume: 156, Issue:3

    Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Angiotensin II; Angiotensin Receptor Antagonists;

1997